News

Epigenomics sheds boss
Enlarge image

BusinessGermany

Epigenomics sheds boss

26.09.2012 - The Berlin-based epigenetics specialist Epigenomics AG has changed its CEO with immediate effect.

Thomas Taapken, formerly CFO will replace his boss Geert Nygaard who will leave the company on September 30.  “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. One year ago, the Berlin-based diagnostics specialist halved its workforce to about 40 staff in the light of a corporate restructuring. Among other things, Epigenomics stopped its own marketing for the Epiprocolon blood test to detect colon cancer in Germany. The focus of the company was turned to the US market where the company runs a clinical study as the basis for a possible FDA approval. The underlying Septin9 marker was out-licensed non-exclusively to a number of partners. However, revenues from this operation do not compensate for the company's development spending. At the end of the second quarter, Epigenomics had €9.1m in cash with a loss of about €5.7m in the first half of 2012

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-03/epigenomics-sheds-boss.html

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF64.7%
  • EPIGENOMICS5.15 EUR47.1%
  • STRATEC BIOMEDICAL48.50 EUR26.5%

FLOP

  • BIOFRONTERA2.52 EUR-13.7%
  • CO.DON2.51 EUR-11.6%
  • ADDEX3.07 CHF-9.7%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 21.11.2014